Federal Register Notice: FDA is making available a draft guidance for industry entitled Safety Testing of Drug Metabolites. The guidance provides recommendations on assessing the safety of unique or major human metabolites of small molecule (nonbiologic) therapeutic products under development. FDA intends the guidance to serve as a resource for general testing considerations and recommendations on the studies’ timing in relation to the clinical development. To download this guidance, click here. To view this notice, click here.
